Back to Clinical Trials
N/AStarting soon

Ovarian Cancer Liquid Biopsy for Early Assessment & Detection in Individuals With BRCA1/2 Pathogenic Variants

Sponsored by Weill Medical College of Cornell University

About this study

The goal of this clinical study is to evaluate the feasibility and acceptability of the Galleri multi-cancer early detection blood test in people with BRCA1 or BRCA2 gene changes who are at high risk for ovarian cancer. The study will also explore how well the test detects ovarian cancer or related precancerous conditions. The main questions it aims to answer are: * Is it feasible to incorporate the Galleri blood test into the care of people at high \* risk for ovarian cancer? * Is the Galleri blood test acceptable to participants? * How well does the Galleri blood test identify ovarian cancer or related precancerous conditions? Participants will: * Receive the Galleri blood test. * Complete questionnaires about their experience with the test. * Some participants will also complete an interview about their experiences and preferences. * Continue with their planned standard medical care, including surgery or follow-up visits, as appropriate.

This is a prospective, multi-center, mixed-methods feasibility study evaluating the integration of the Galleri multi-cancer early detection (MCED) liquid biopsy into hereditary cancer risk management for individuals at increased risk of epithelial ovarian cancer due to pathogenic or likely pathogenic BRCA1 or BRCA2 variants. The study also includes individuals with a prior diagnosis of serous tubal intraepithelial carcinoma (STIC), a precursor lesion associated with an increased risk of subsequent ovarian, fallopian tube, or primary peritoneal cancer. The primary objective is to evaluate the feasibility of incorporating liquid biopsy testing into clinical care. Secondary objectives include evaluating participant acceptability, identifying barriers and facilitators to implementation, and g…

Where this study is enrolling (2)

Who can participate

Inclusion criteria

  • ✓Cohort A participants must meet all of the following criteria:
  • ✓1. Age ≥ 35 years (based on current National Comprehensive Cancer Network guidelines35 for risk-reducing gynecologic surgery) with no upper age limit
  • ✓2. Confirmed germline PV or likely PV in the BRCA1 or BRCA2 genes, documented by CLIA-certified genetic testing.
  • ✓3. Scheduled to undergo risk-reducing gynecologic surgery (salpingo-oophorectomy or salpingectomy with or without hysterectomy) at the study site.
  • ✓4. Willing and able to provide informed consent in English This initial phase is limited to English-speaking participants. This limitation is due to feasibility considerations for initial qualitative instrument validation; future phases will incorporate translated materials
  • ✓Cohort B participants must meet all of the following criteria:
  • ✓5. Age ≥ 35 years with no upper age limit.
  • ✓6. STIC lesion previously identified on surgical pathology within the prior 10 years.
  • ✓7. Willing and able to undergo baseline and annual research blood draws for up to 10 years following STIC lesion diagnosis.
  • ✓8. Willing and able to provide informed consent in English

Exclusion criteria

  • ✕Cohort A:
  • ✕1. Pregnant or breastfeeding at the time of enrollment.
  • ✕2. Prior removal of bilateral fallopian tubes and/or bilateral ovaries.
  • ✕3. Active diagnosis of cancer.
  • ✕4. Prior or active diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer at the time of consent.
  • ✕5. Patients with a history of cancer are eligible when \> 2 years no evidence of disease.
  • ✕6. Inability to provide informed consent.
  • ✕7. Concurrent participation in another interventional trial that may confound study outcomes.
  • ✕Cohort B:
  • ✕1. Pregnant or breastfeeding at the time of enrollment.
  • ✕2. Active diagnosis of cancer.
  • ✕3. Prior or active diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer at the time of consent (prior STIC lesion is NOT a contraindication to enrollment).
  • ✕4. Patients with a history of cancer are eligible when \> 2 years no evidence of disease.
  • ✕5. Inability to provide informed consent.
  • ✕6. Concurrent participation in another interventional trial that may confound study outcomes.

Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.

Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.

Trial data sourced from ClinicalTrials.gov.